The big business of blood got even bigger during Covid.
The New York Blood Center notched a nearly $50 million surplus during the first 12 months of the pandemic as its plasma business quintupled, according to a Crain’s analysis of the nonprofit’s most recent audited financial filings.
Operating revenue from whole blood and blood products increased by 8% to $525 million, accounting for most of the center’s $554 million in operating revenue for the fiscal year, which ran through March 2021. Operating expenses came in just below $505 million.
Revenue from plasma, a blood derivative known as “liquid gold” for its color, jumped
→ Continue reading at Crain's New York Business